Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
Date:8/1/2013

other drugs targeting the sphingosine 1-phosphate subtype 1 (S1P1) receptor. Further evaluation of the data is ongoing.

Second Quarter 2013 Financial Results

  • Revenues totaled $68.9 million, including $1.3 million in net product sales and $65.5 million in milestone payments.
  • Research and development expenses totaled $18.8 million.
  • General and administrative expenses totaled $8.6 million.
  • Net income allocable to common stockholders was $40.1 million, or $0.18 per share.
  • At June 30, 2013, cash and cash equivalents totaled $178.9 million and approximately 218.2 million shares of common stock were outstanding.
  • Scheduled Conference Call and WebcastArena will host a conference call and webcast to provide a corporate update and report second quarter 2013 financial results today at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Second Quarter 2013 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

    Upcoming Conference ParticipationArena is planning to participate at upcoming investment and industry conferences, including:

  • Bank of America Merrill Lynch Global Healthcare Conference, September 11-13, 2013, London, England
  • 49th Annual Meeting of the European Association for the Study of Diabetes, September 23-27, 2013, Barcelona, Spain
  • NewsMakers in the Biotech Industry, September 27, 2013, New York, New Y
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, August 1
    2. Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference
    3. Former Semi-Pro Arena Football Player Bridged to Heart Transplant with the SynCardia Total Artificial Heart
    4. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
    5. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
    6. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
    7. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
    8. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
    9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
    10. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
    11. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
    (Date:8/29/2014)... , Aug. 29, 2014  In part ... to leverage a hospital pharmacy as a strategic asset, ... national practice leader for Cardinal Health,s Innovation Delivery Solutions ... care can benefit both hospitals and patients. ... only one part of their job in a value-based ...
    (Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Soft Tissue Repair Devices Market 2014-2018" report to ... the mass of cells that connect, support, or surround ... such as tendons, ligaments, cartilage, fascia, and other fibrous ... these tissues with age result in wear and tear ...
    Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
    ... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
    ... 14 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH), provides ... in the company,s name, ticker symbol and CUSIP number. ... FINRA all documentation requested in connection with the name change, ... number for the company,s common shares. FINRA is working ...
    Cached Medicine Technology:AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change 2
    (Date:8/30/2014)... 2014 Continuing to meet the skin ... with the addition of a new doctor and office ... provided leading-edge skin care in Grand Rapids since 1980 ... “As a doctor, my passion is making sure my ... Forefront Dermatology, I’m better able to focus on my ...
    (Date:8/30/2014)... 2014 Hastings and Hastings, a qualified ... throughout Arizona is pleased to report having saved a ... example among many cases where Hastings and Hastings has ... retain a greater portion of their settlement or recovery. ... a positive solution for Arizona car accident victims is ...
    (Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Lab ... The report then explores global and China’s top ... capacity, production value, and market share etc. , ...
    (Date:8/30/2014)... York (PRWEB) August 30, 2014 Bringing ... Profit By Search announces the Labor Day discount ... clients will surely get the complete services related to ... SEO professionals, Content Writers, and others do have a ... perfection that reflects in their work and since the ...
    (Date:8/30/2014)... lead extraction (TLE) is clinically successful in more than ... Lead Extraction ConTRolled (ELECTRa) registry presented for the first ... Grazia Bongiorni, chair of the registry,s executive committee. , ... devices (CIED) implant procedures has grown in recent years. ... increased and leads are often the cause. TLE is ...
    Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3
    ... better with heart failure, says a new study. // ... analysed the records of over 100,000 patients hospitalised because their ... Scientist. , ,They found that the fatter the person, ... hospital stay. The researchers reported their findings in the latest ...
    ... Since August 2006, Hong Kong authorities have been warning residents ... infections on fish eggs and considered dangerous for human health. ... the mainland have tested positive for malachite green. ... is the biggest mainland fish marketer, shipping a total of ...
    ... 1,000 children around the world were infected by HIV in each ... // ,In total, around 410,000 to 660,000 children under ... U.N. agency said. ,The report added that most of ... HIV-positive mothers and about half of the children infected last year ...
    ... the World Health Organization's tuberculosis drug-resistant unit, this week ... Washington, D.C., to discuss funding to combat extensively drug-resistant ... first- and second-line drugs -- VOA News reports. ... combat XDR-TB in Africa is roughly $300 million over ...
    ... increasingly important method for detecting malaria. Health specialists recommend ... other strategies for controlling the disease // , including ... indoor spraying against malaria-carrying mosquitoes and testing and treatment ... tests are ideal for rural areas are accurate, easy ...
    ... Researchers find that aspirin saves the life of cancer ... believe that majority of these patients will die// if ... turns common medical assumptions upside down and will likely ... thin blood and cancer patients experience low platelet counts ...
    Cached Medicine News:Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3Health News:Aspirin Saves Life Even in Cancer Patients 2Health News:Aspirin Saves Life Even in Cancer Patients 3
    ... while minimizing the pain of ... safety-engineered BD Microtainer Genie Lancet. ... offers a full range of ... blood collection and protects the ...
    The DiaSTAT™ is an automated liquid chromatography system designed for the rapid and automated analysis of hemoglobin A1C. Ideal for low and ,medium volume testing environments....
    The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia...
    Inquire...
    Medicine Products: